Pharmacologic evaluation of loratadine (SCH 29851), chlorpheniramine and placebo

Eur J Clin Pharmacol. 1986;31(2):247-50. doi: 10.1007/BF00606669.

Abstract

The antihistaminic effect of loratadine (160 mg) was compared in twenty-four normal male volunteers to chlorpheniramine maleate (4 mg) and placebo in a double blinded 3-way cross-over study of latin square design. After receiving single oral doses of each medication, the wheal response to serial 0.1 ml intradermal histamine (2 micrograms) and saline (control) injections were recorded over a 24-h period. The calculated wheal areas were compared to base-line measurements. The results were analyzed by analysis of variance. Loratadine exhibited a more pronounced inhibition of histamine wheal formation than placebo or chlorpheniramine maleate (p less than 0.003). In contrast to chlorpheniramine maleate which had a duration of action of only 3 h, loratadine inhibited the response for the entire observation period between 1 and 24 h post-dose. Although sedation was observed less frequently with loratadine (Placebo, n = 2; chlorpheniramine, n = 3; and loratadine, n = 1), the relative incidence were not statistically significant.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Chlorpheniramine / pharmacology*
  • Cyproheptadine / analogs & derivatives*
  • Cyproheptadine / pharmacology
  • Double-Blind Method
  • Histamine H1 Antagonists*
  • Humans
  • Intradermal Tests
  • Loratadine
  • Male
  • Random Allocation

Substances

  • Histamine H1 Antagonists
  • Cyproheptadine
  • Chlorpheniramine
  • Loratadine